Kingir Ege, Sevinc Cem, Unal Gunes
Behavioral Neuroscience Laboratory, Department of Psychology, Boğaziçi University, 34342, Istanbul, Turkey.
Behavioral Neuroscience Laboratory, Department of Psychology, Boğaziçi University, 34342, Istanbul, Turkey.
Neuropharmacology. 2023 May 1;228:109468. doi: 10.1016/j.neuropharm.2023.109468. Epub 2023 Feb 20.
Acute injections of ketamine lead to rapid but transient antidepressant effects. Chronic oral treatment at low doses, a promising non-invasive alternative, may prolong this therapeutic effect. Here, we examine the antidepressant effects of chronic oral ketamine in rats under chronic unpredictable mild stress (CUMS), and reveal their neuronal correlates. Male Wistar rats were divided into control, ketamine, CUMS, and CUMS-ketamine groups. The CUMS protocol was applied to the latter two groups for 9 weeks, and ketamine (0.013 mg/ml) was provided ad libitum to the ketamine and CUMS-ketamine groups for 5 weeks. The sucrose consumption test, forced swim test, open field test, elevated plus maze, and Morris water maze were respectively used to assess anhedonia, behavioral despair, general locomotor activity, anxiety-like behavior and spatial reference memory. CUMS caused a reduction of sucrose consumption and impaired spatial memory, accompanied by increased neuronal activation in the lateral habenula (LHb) and paraventricular thalamic nucleus (PVT). Oral ketamine prevented behavioral despair and CUMS-induced anhedonia. Reward-triggered c-Fos immunoreactivity was decreased in the LHb and increased in the nucleus accumbens shell (NAcSh) in the CUMS-ketamine group compared to the CUMS group. Ketamine did not produce a differential effect in the OFT, EPM and MWM. These results show that chronic oral ketamine at low doses prevents anhedonia without impairing spatial reference memory. The observed neuronal activation changes in the LHb and NAcSh may be involved in the preventive effects of ketamine on anhedonia. This article is part of the Special Issue on "Ketamine and its Metabolites".
急性注射氯胺酮会产生迅速但短暂的抗抑郁作用。低剂量慢性口服治疗是一种有前景的非侵入性替代方法,可能会延长这种治疗效果。在此,我们研究了慢性不可预测温和应激(CUMS)条件下慢性口服氯胺酮对大鼠的抗抑郁作用,并揭示其神经元相关性。雄性Wistar大鼠被分为对照组、氯胺酮组、CUMS组和CUMS - 氯胺酮组。后两组应用CUMS方案9周,氯胺酮组和CUMS - 氯胺酮组自由饮用含氯胺酮(0.013毫克/毫升)的水5周。分别使用蔗糖消耗试验、强迫游泳试验、旷场试验、高架十字迷宫试验和莫里斯水迷宫试验来评估快感缺失、行为绝望、一般运动活动、焦虑样行为和空间参考记忆。CUMS导致蔗糖消耗减少和空间记忆受损,同时外侧缰核(LHb)和室旁丘脑核(PVT)的神经元激活增加。口服氯胺酮可预防行为绝望和CUMS诱导的快感缺失。与CUMS组相比,CUMS - 氯胺酮组中,LHb中奖励触发的c - Fos免疫反应性降低,伏隔核壳(NAcSh)中增加。氯胺酮在旷场试验、高架十字迷宫试验和莫里斯水迷宫试验中未产生差异效应。这些结果表明,低剂量慢性口服氯胺酮可预防快感缺失而不损害空间参考记忆。在LHb和NAcSh中观察到的神经元激活变化可能参与了氯胺酮对快感缺失的预防作用。本文是“氯胺酮及其代谢产物”特刊的一部分。